In the treatment of prostate cancer, myricetin promotes prostate cancer cell apoptosis and antimetastatic effects by inhibiting PIM1 and by disrupting its interaction with CXCR4 (Ye et al., 2018). The gene discussed is CXCR4; the disease is Familial prostate cancer.